11:21 AM EST - QLT : The biopharmaceutical group, reported Thursday that its anti-blindness treatment Visudyne fell 29 percent in the fourth quarter, the company said on Thursday, citing figures from its global marketing partner, drug giant Novartis. QLT said Novartis reported sales of Visudyne of $76.5 million for the quarter, down from $108 million a year earlier. QLT
shares T.QLT are trading unchanged at $10.20.
